Table 4.

Associations by multivariate logistic regression analyses of gender, IV drug use duration, viral co-infection status, and CCL3L1 copy number with HCV serostatus

Covariate	Model 1	Model 2	Model 3	Model 4	Model 5
	OR; 95% CI	OR; 95% CI	OR; 95% CI	OR; 95% CI	OR; 95% CI
	P	P	P	P	P
Gender
Male*	1.0	1.0	1.0	1.0	1.0
Female	0.493; 0.252–0.966	0.412; 0.122–1.39	0.288; 0.075–1.106	0.488; 0.249–0.958	0.512; 0.18–1.458
	0.0394	0.1528	0.0698	0.0370	0.2100
HIV status
HIV−*	1.0	1.0	1.0	1.0
HIV+	2.088; 1.217–3.583	**	**	2.159; 1.246–3.738
	0.0075	0.9333	0.9282	0.0060
HBV status
HBV−*	1.0	1.0	1.0	1.0
HBV+	2.535; 0.950–6.760	1.549; 0.159–15.113	2.549; 0.255–25.474	2.551; 0.956–6.808
	0.0631	0.7066	0.4257	0.0615
IV drug use duration
Yearsa		1.272; 1.125–1.439	1.331; 1.158–1.531		1.351; 1.191–1.534
		0.0001	<0.0001		<0.0001
CCL3L1 copy number
0–2*			1.0	1.0	1.0
3–6			7.64; 2.052–28.447	1.248; 0.641–2.429	2.995; 0.91–9.862
			0.0024	0.5148	0.0712

NOTE. Models #1-5 depict multivariate logistic regression analyses with the indicated covariates with outcome of HCV serostatus.

^*reference group.

^**values reflected those of correlated variables (OR >999.99; 95% CI: <0.001–>999.99). OR, odds ratio; CI, confidence interval; P, significance value.

^aYears was categorized as a continuous variable in full-years, and data reflects an increase in OR with each additional year of IV drug use.